SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
153.87
+5.64 (+3.80%)
At close: 4:00PM EDT

153.87 0.00 (0.00%)
After hours: 5:13PM EDT

Stock chart is not supported by your current browser
Previous Close148.23
Open148.82
Bid150.00 x 900
Ask157.00 x 800
Day's Range148.72 - 154.06
52 Week Range59.57 - 195.97
Volume357,369
Avg. Volume520,067
Market Cap7.18B
Beta3.59
PE Ratio (TTM)N/A
EPS (TTM)-5.57
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est220.64
Trade prices are not sourced from all markets
  • Business Wire14 days ago

    Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress

    Conditional acceptance granted by U.S. Food and Drug Administration for the proprietary name ZULRESSO™ for Sage’s intravenous formulation of brexanolone

  • ACCESSWIRE14 days ago

    SAGE Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / SAGE Therapeutics, Inc. (NASDAQ: SAGE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:00:00 AM Eastern ...

  • Business Wire18 days ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 93,600 shares of its common stock to 16 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Business Wire20 days ago

    Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference

    Sage Therapeutics  , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the Company will present at the Canaccord 38th Annual Growth Conference on Wednesday, August 8, 2018 at 11:00 A.M.

  • FDA Approves United Therapeutics’ Implantable System for Remodulin
    Market Realist21 days ago

    FDA Approves United Therapeutics’ Implantable System for Remodulin

    Today, the FDA approved United Therapeutics’ (UTHR) new drug application for its Implantable System for Remodulin (or ISR).

  • Business Wire28 days ago

    Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

    Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 7, 2018 at 8:00 A.M.

  • Sage Therapeutics’ NMDA Receptor–Based Products
    Market Realistlast month

    Sage Therapeutics’ NMDA Receptor–Based Products

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders. One of the products under development, SAGE-718, is based on its NMDA Receptor program.

  • Sage Therapeutics’ Product Portfolio in July
    Market Realistlast month

    Sage Therapeutics’ Product Portfolio in July

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders. The chart below shows the products under development, based on the drug discovery programs for Sage Therapeutics. The company classifies its products into two programs: GABA receptors and NMDA receptors. 

  • Sage Therapeutics: Analysts’ Estimates and Recommendations
    Market Realistlast month

    Sage Therapeutics: Analysts’ Estimates and Recommendations

    Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company. Sage Therapeutics develops medicines for the treatment of life-altering central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • Cramer Remix: Investors can't see the reality of this market
    CNBClast month

    Cramer Remix: Investors can't see the reality of this market

    Jim Cramer makes the case to value the market just as it is.

  • CNBClast month

    Cramer Remix: Investors can't see the reality of this market

    CNBC's Jim Cramer makes the case to value the market just as it is. The "Mad Money" host also hears from the CEOs of Sage Therapeutics and Vistra Energy. In the lightning round, Cramer makes the case for buying shares of World Wrestling Entertainment.

  • 3 Top Biotech Stocks to Buy for the 2nd Half of 2018
    Motley Foollast month

    3 Top Biotech Stocks to Buy for the 2nd Half of 2018

    Consider putting these large-cap, mid-cap, and small-cap biotech stocks on your buy list.

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

    Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...

  • Business Wire2 months ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 129,000 shares of its common stock to 31 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...

  • SAGE Therapeutics’ NMDA Receptor–Based Portfolio
    Market Realist2 months ago

    SAGE Therapeutics’ NMDA Receptor–Based Portfolio

    As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.

  • SAGE Therapeutics’ GABA Receptor–Based Portfolio
    Market Realist2 months ago

    SAGE Therapeutics’ GABA Receptor–Based Portfolio

    As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.

  • A Look at SAGE Therapeutics’ Product Portfolio
    Market Realist2 months ago

    A Look at SAGE Therapeutics’ Product Portfolio

    SAGE Therapeutics (SAGE) includes two different programs based on the modulation of GABAA (gamma-Aminobutyric acid) and NMDA (N-methyl-D-aspartate) receptors for the treatment of life-threatening central nervous system disorders. Let’s have a look at the details of these programs.

  • SAGE Therapeutics’ Strategic Collaboration with Shionogi
    Market Realist2 months ago

    SAGE Therapeutics’ Strategic Collaboration with Shionogi

    On June 13, SAGE Therapeutics (SAGE) announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217. Let’s take a look at the details of the collaboration.

  • SAGE Therapeutics’ Stock Performance and Estimates in June
    Market Realist2 months ago

    SAGE Therapeutics’ Stock Performance and Estimates in June

    SAGE Therapeutics (SAGE), a clinical research–based biopharmaceutical company, develops drugs for the treatment of life-threatening central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • MarketWatch2 months ago

    Sage shares drop 3% after $90 mln Shionogi deal for key drug

    Sage Therapeutics Inc. shares dropped 3.3% in Thursday morning trade after the company announced a $90 million deal with Shionogi & Co. Ltd. for the clinical development and commercialization of its drug SAGE-217 in Japan, Taiwan and South Korea. Shionogi will also handle clinical development, regulatory filings and commercialization of SAGE-217 for major depressive disorder and any other indications in those countries.

  • Business Wire2 months ago

    Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for SAGE-217 in the U.S. with a pivotal Phase 3 placebo-controlled trial in patients with MDD expected to commence this year, and an ongoing placebo-controlled trial in women with PPD, now also designated a pivotal trial.

  • Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug
    Investor's Business Daily2 months ago

    Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug

    Sage Therapeutics lost some of its steam Wednesday, as shares dropped more than 3%, but analysts remained bullish on the biotech company's plans for an acute depression treatment.

  • Company News For Jun 13, 2018
    Zacks2 months ago

    Company News For Jun 13, 2018

    Companies In The News are: TSLA,SAGE,RH,PLAY

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Sage Therapeutics and Galmed Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 13, 2018 / It was an exciting day for biotech stocks Sage Therapeutics and Galmed Pharmaceuticals. Sage rose higher after announcing that the FDA has allowed expedited development on its major depressive drug. Shares of Galmed soared to a new high after announcing positive results from its Phase 2b ARREST study.